On Tuesday Moderna Inc announced that they have begun to study the COVID vaccine (mRNA-1273) in children as young as 6 months, to as old as 12 years.
The study will enroll approximately 6,750 children in the United States and Canada and will test the effectiveness and safety on 2 doses of the vaccine given 28 days apart.
The vaccine has currently been approved for emergency use in the United States for individuals over the age of 18.
In December of 2020, Moderna had already begun to test the vaccine on adolescents ages 12 – 18.
The study is being overseen in collaboration with the National Institute of Allergy and Infectious Diseases and Biomedical and Advanced Research and Developmental Authority.
We just announced that the first participants have been dosed in the Phase 2/3 study, called the KidCOVE study, of mRNA-1273, our vaccine candidate against COVID-19, in children ages 6 months to less than 12 years. Read more: https://t.co/FpQ2NCcRxR pic.twitter.com/oWZ0UET8e1
— Moderna (@moderna_tx) March 16, 2021